Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 3/20 | 0.77 |
| ▸ | HRH3 | Q9Y5N1 | 9/20 | 0.53 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.47 |
| ▸ | HRH1 | P35367 | 1/20 | 0.47 |
| ▸ | MAOB | P27338 | 5/20 | 0.47 |
| ▸ | MAOA | P21397 | 4/20 | 0.47 |
| ▸ | USP2 | O75604 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.43 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.43 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.43 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.43 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.43 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.43 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19764434 | 0.93 | KDM1A (0.78) | KDM1AHRH3CYP2D6HRH1MAOB | |
| SCHEMBL17988112 | 0.87 | KDM1A (1.00) | KDM1AHRH3CYP2D6HRH1MAOB | |
| SCHEMBL12389735 | 0.83 | KDM1A (0.71) | KDM1AHRH3MAOBMAOA | |
| SCHEMBL17988101 | 0.83 | KDM1A (0.71) | KDM1AHRH3MAOBMAOA | |
| SCHEMBL17988097 | 0.82 | KDM1A (0.65) | KDM1AHRH3MAOBMAOA | |
| SCHEMBL17988042 | 0.80 | KDM1A (1.00) | KDM1AHRH3CYP2D6HRH1MAOB | |
| SCHEMBL17988159 | 0.76 | KDM1A (0.72) | KDM1AHRH3CYP2D6MAOBMAOA | |
| SCHEMBL12389732 | 0.76 | KDM1A (0.55) | KDM1A | |
| SCHEMBL17988029 | 0.76 | KDM1A (1.00) | KDM1A | |
| SCHEMBL17963557 | 0.76 | KDM1A (0.67) | KDM1AMAOBMAOAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180009735-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2018-01-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180009735-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | KDM1B, HDAC1, DOT1L | KDM1A 7/4885HRH3 589/4885CYP2D6 2782/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.